PT  - JOURNAL ARTICLE
AU  - MacKenna, Brian
AU  - Bacon, Seb
AU  - Walker, Alex J
AU  - Curtis, Helen J
AU  - Croker, Richard
AU  - Goldacre, Ben
TI  - Impact Of Electronic Health Record Interface Design On Unsafe Prescribing Of Ciclosporin, Tacrolimus and Diltiazem: A Cohort Study In English NHS Primary Care
AID  - 10.1101/19011957
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19011957
4099  - http://medrxiv.org/content/early/2019/11/12/19011957.short
4100  - http://medrxiv.org/content/early/2019/11/12/19011957.full
AB  - Background In England, national safety guidance recommends that ciclosporin, tacrolimus and diltiazem are prescribed by brand name due to their narrow therapeutic windows and, in the case of tacrolimus, to reduce the chance of organ transplantation rejection. Various small studies have shown that changes to electronic health records (EHR) interface can affect prescribing choices.Objectives Our objectives were to assess variation by EHR system in breaches of safety guidance around prescribing of ciclosporin, tacrolimus and diltiazem; and to conduct user-interface research into the causes of such breaches.Methods We carried out a retrospective cohort study using prescribing data in English primary care. Participants were English general practices and their respective electronic health records. The main outcome measures were (1) variation in ratio of breaching / adherent prescribing all practices (2) description of observations of EHR usage.Results A total of 2,575,411 prescriptions were issued in 2018 for ciclosporin, tacrolimus and diltiazem (over 60mg); of these, 316,119 prescriptions breached NHS guidance (12.3%). Breaches were most common amongst users of the EMIS EHR (in 23.2% of ciclosporin & tacrolimus prescriptions, and 22.7% of diltiazem prescriptions); but breaches were observed in all EHRs.Conclusion Design choices in EHR strongly influence safe prescribing of ciclosporin, tacrolimus and diltiazem; and breaches are prevalent in general practices in England. We recommend that all EHR vendors review their systems to increase safe prescribing of these medicines in line with national guidance. Almost all clinical practice is now mediated through an EHR system: further quantitative research into the effect of EHR design on clinical practice is long overdue.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: BG has received research funding from the Laura and John Arnold Foundation, the Wellcome Trust, the Oxford Biomedical Research Centre, the National Institute for Health Research Applied Research Collaboration Oxford and Thames Valley, the NHS National Institute for Health Research School of Primary Care Research, the Health Foundation, Health Data Research UK, the Mohn-Westlake Foundation, and the World Health Organisation; he also receives personal income from speaking and writing for lay audiences on the misuse of science. RC, AJW, HC, SB are employed on BG’s grants for OpenPrescribing. BMK is seconded to the DataLab from NHS England. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR, NHS England, or the Department of Health and Social Care. Funding StatementNo specific funding was sought for this work. BG’s work on clinical informatics has been supported by The NIHR Biomedical Research Centre, Oxford; NHS England; the Health Foundation (Award Reference Number 7599); the National Institute for Health Research (NIHR) School of Primary Care Research (SPCR) (Award Reference Number 327); the NIHR Applied Research Collaboration Oxford and Thames Valley; Health Data Research UK; and policy work by the Mohn-Westlake Foundation. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available in a public, open access repository on Github. https://github.com/ebmdatalab/software_differences_paper CCGClinical Commissioning GroupEHRElectronic Health RecordsMHRAMedicines and Healthcare products Regulatory AgencyNHSNational Health Service